PHVS
Live News • Jun 16
Pharvaris Stock Draws Attention as Deucrictibant Phase 3 Data Highlights HAE Advances Pharvaris highlighted eight abstracts at the 2026 EAACI Congress, centered on deucrictibant for hereditary angioedema (HAE), including Phase 3 and long-term safety results.
RAPIDe-3 Phase 3 data showed rapid and sustained efficacy of deucrictibant in both on-demand and prophylactic HAE treatment settings, with most attacks addressed using a single capsule.
The company reported a favorable safety profile for deucrictibant and is progressing commercialization preparations, with recent clinical and pipeline updates linked to strong stock returns and some valuation models indicating the stock may be undervalued, even as other market metrics point to a premium.
The breadth of data Pharvaris brought to EAACI, spanning Phase 3 efficacy and longer-term safety for deucrictibant, underscores that the HAE program is moving into a more mature stage. Commercial planning is increasingly relevant in this context.
Investors will likely focus on how upcoming regulatory and launch milestones align with current valuation work. This is particularly important given the mix of views that Pharvaris stock is both undervalued on some models and already pricing in a premium on others. Announcement • Jun 15
Pharvaris Presents Data Supporting Differentiated Profile of Deucrictibant in HAE Management at EAACI 2026 Pharvaris summarized the presentations from the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, which took place from June 12-15, 2026, in Istanbul, Turkey. Results from prespecified assessment of End of Progression™ in the RAPIDe-3 Phase 3 study and clinical relevance of this newly-defined endpoint were detailed in an oral presentation. Evidence on the cardiovascular safety profile of deucrictibant in clinical studies to date was presented. Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial was presented. The RAPIDe-3 global Phase 3, placebo-controlled study (NCT06343779) evaluated orally administered deucrictibant immediate-release capsule (20 mg) for the on-demand treatment of attacks in participants 12 years and older with HAE, including those with HAE with normal C1 inhibitor. Results from RAPIDe-3 demonstrated the rapid and sustained efficacy of deucrictibant in treating HAE attacks. The median time to onset of symptom relief was 1.28 hours with deucrictibant treatment versus over 12 hours with placebo. The median time to complete resolution of attack symptoms was 11.95 hours with deucrictibant treatment versus over 48 hours with placebo. The majority of deucrictibant-treated attacks achieved the efficacy endpoints with a single capsule. 83.0% of deucrictibant-treated attacks were treated with a single capsule of deucrictibant and 93.2% did not require conventional treatment as rescue medication. Deucrictibant was well tolerated with no treatment-related serious adverse events and no participants discontinuing treatment due to treatment-emergent adverse events. Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial was presented as an oral presentation. RAPIDe-3 is the first and only study to date to have assessed End of Progression™ (EoP), a clinically meaningful measure of early treatment response defined as the earliest timepoint at which symptoms stop worsening, as a prespecified endpoint. Treatment with deucrictibant resulted in a median time to EoP of 17.47 minutes, compared with 228.67 minutes with placebo, and EoP was achieved within 12 hours in 92.8% of deucrictibant-treated attacks versus 60.9% of attacks treated with placebo. The majority of attacks achieving EoP reached this endpoint with a single capsule (97.4%) of oral deucrictibant. RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks was presented. Qualitative in-trial interviews conducted with participants during the RAPIDe-3 study captured high-quality patient experience data, including insights into the experiences of people living with HAE related to their attacks and associated health-related quality of life (HRQoL) impacts. Overall, participants reported experiencing eight negatively impacted HRQoL domains with HAE attacks during the study; the most frequently reported were fatigue, emotional wellbeing, and activities of daily living. Despite using effective and well-tolerated HAE treatments in the past, 45.7% of participants reported that deucrictibant-treated attacks had improved treatment experience in day-to-day life compared with prior attacks treated with injectable standard-of-care HAE treatments. Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule was presented. Data assessed human exposures across the anticipated dosing scenarios of deucrictibant IR in combination with deucrictibant XR and calculated the corresponding safety margins based on available clinical and nonclinical data. The analysis demonstrated that combined use of a 40 mg deucrictibant XR tablet for prophylaxis and one or two deucrictibant IR 20 mg capsule(s), in the event of a breakthrough attack while on prophylaxis, is supported by evidence of adequate safety margins. Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema was presented. Final data from the completed open-label extension (OLE) of the Phase 2 CHAPTER-1 (NCT05047185) study investigating oral deucrictibant demonstrated sustained efficacy and a favorable long-term safety profile, with participants treated for up to approximately 34 months prior to rolling over to the CHAPTER-4 (NCT06679881), a long-term, open-label extension study of deucrictibant XR for the prophylactic treatment of HAE attacks. Deucrictibant was generally well tolerated, with no treatment-related serious adverse events, discontinuations, or clinically meaningful laboratory, vital sign, or ECG abnormalities reported. Treatment led to rapid and durable reductions in HAE attack rates, with attack frequency reduced on average by approximately 92% from study baseline and remaining low over time, and approximately half of participants being attack-free during the entire extension period. CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema was presented. Findings from CHAPTER-1 provided evidence of sustained improvement in disease control, HRQoL, and treatment satisfaction in participants with HAE. Disease control improved rapidly and was durable, with 100% of participants reporting well-controlled disease during long-term treatment (Week 62 to end of study). Treatment satisfaction scores for effectiveness were higher versus placebo and remained consistently high through week 134. Clinically meaningful improvements in HRQoL were observed as by week four and were maintained through more than two years of treatment, with all participants reporting improved HRQoL during the OLE. Clinical Cardiovascular Safety Assessment of Oral Deucrictibant was presented. An integrated analysis assessed cardiovascular (CV) outcomes across all deucrictibant clinical studies with available data at the time of the analyses and included approximately 570 unique deucrictibant-treated participants. 
